Objectives. We sought to describe Neisseria meningitidis immunity and its association with pharyngeal carriage in Burkina Faso, where N. meningitidis serogroup W-135 and serogroup A disease are hyperendemic and most of the population received polysaccharide A/C vaccine during 2002.
In the African meningitis belt, Neisseria meningitidis serogroup A has been the most frequent cause of bacterial meningitis, and mass immunization campaigns with polysaccharide A/C vaccine have been conducted for epidemic control [1] . Since 2000, serogroup W-135 meningococcal disease has increased from sporadic [2] to epidemic incidence [3, 4] , suggesting that, in the African meningitis belt, vaccines may need to include antigens from this serogroup as well. However, much of the information that would help inform a decision about this inclusion is lacking. For example, anti-W-135 antibody seroprevalence and the immune response to serogroup W-135 antigen after natural or vaccine exposure are not well known, and a recent vaccine study of young children in Saudi Arabia showed poor putatively protective antibody titers after polysaccharide W-135 vaccination [5] .
For serogroups A, B, and C, pharyngeal carriage is considered to be an immunizing process [6] [7] [8] [9] , and antibodies induced by serogroup C conjugate vaccine can protect against carriage [10] . A similar finding for serogroup W-135 would suggest that indirect disease prevention could be obtained through a reduction in carriage prevalence and thus provide support for conjugate W-135 vaccine use.
During the meningitis season of 2003, we studied the association between meningococcal carriage and antimeningococcal immune protection in young people in urban BoboDioulasso, Burkina Faso (435,000 inhabitants), where, since 2002, serogroup W-135 has been a major agent of meningococcal disease [11] .
SUBJECTS, MATERIALS, AND METHODS
Recruitment and clinic visits. Ten of 22 urban neighborhoods in Bobo-Dioulasso were selected randomly, and 25 crossroads in each neighborhood were randomly chosen as starting points. At each starting point, the street of recruitment was randomly determined, and the compounds along this street were visited, starting with the first compound after the crossroad. In each compound, a list of inhabitants aged either 4-14 years or 15-29 years was established, and 1 participant was randomly chosen from each age group. If the chosen person refused to participate or if the age group was not represented in the compound, the neighboring compound was visited. Persons with long-term travel plans, residence outside urban Bobo-Dioulasso, non-African ethnicity, or severe disease (including hemophilia) were excluded.
The study was approved by the Ethics Committee of Centre Muraz, Bobo-Dioulasso, Burkina Faso, and by the Comité de Vigilance of Pasteur Institute Paris. Participants or their guardians (for those !18 years old) provided written, informed consent. After written, informed consent was obtained, a baseline questionnaire that determined the medical history of participants and their families during the preceding year was administered. During 3 February-7 June 2003, all participants were invited to attend 5 evaluations, occurring at an average interval of 4 weeks, at the Centre Muraz outpatient clinic. At each clinic visit, a questionnaire on recent medical history was administered. Weight and height were measured for children р8 years old, and malnutrition was defined as a weight:height ratio below the third percentile. At all 5 visits, swab samples were obtained from the posterior pharyngeal wall via the mouth, using cotton-tipped sterile swabs, which were streaked immediately onto selective medium. The plates were stored immediately in a 5% CO 2 atmosphere at room temperature for a maximum of 2 h until incubation at 37ЊC. At visits 1 and 5, a 2-5-mL blood sample was obtained and stored at 8ЊC, until centrifugation was performed up to 4 h later. After centrifugation was performed, serum samples were frozen at Ϫ80ЊC until further analysis.
Microbiological analyses. Isolation and identification of meningococci from incubated plates was performed using established bacteriological methods [12] . From each incubated plate with colonies suspicious for Neisseria species by aspect, 3 bacterial colonies were selected for Gram stain and oxidase and biochemical testing. Confirmation of N. meningitidis was based on the results of polymerase chain reaction (PCR) testing [13] by amplification of the crgA gene [14, 15] . For meningococcal genogroup prediction, multiplex followed by simplex PCR was performed using oligonucleotides for the siaD gene (for serogroups B, C, W-135, and Y) and the mynB gene (for serogroup A) [3] . All N. meningitidis isolates were tested for serogroup confirmation with immune serum by use of either a commercial product (bioMérieux) or rabbit polyclonal antibodies absorbed onto killed Staphylococcus aureus suspension (Health Protection Agency, Manchester, United Kingdom).
Serological analyses. Serogroup-specific IgG concentrations were determined in serum by use of a tetraplex IgG bead assay for serogroups A, C, W-135, and Y [16] . The calibration factors of the standard CDC1992 serum for N. meningitidisspecific IgG used were 91.8 mg/mL for serogroup A, 24.1 mg/ mL for serogroup C [17] , 25.23 mg/mL for serogroup W-135, and 28.92 mg/mL for serogroup Y [18] . The lower limits of detection for serogroups A, C, W-135, and Y were 0.08, 0.06, 0.065, and 0.075 mg/mL, respectively. Serum bactericidal antibody (SBA) was measured using baby rabbit complement (Pel-Freeze) as an exogenous source of complement, as described elsewhere [19] . The strains used were F8238 (A:4: P1.20,9) for serogroup A and M,01.0240070 (W-135:NT:P1.18-1,3) for serogroup W-135. SBA titers were expressed as the reciprocal of the final serum dilution giving у50% killing at 60 min, for serogroup W-135, and 90 min, for serogroup A. For computational purposes, titers !4 were assigned a value of 2.
Statistical analyses. Only participants from whom baseline serum samples were collected were included in the analyses. Four-month carriage prevalence was defined as the presence of N. meningitidis on at least 1 occasion during the study period, and this analysis included only participants with carriage information from all 5 visits. For the determination of carriage prevalence and the effect of immune status on carriage, participants receiving penicillin, cotrimoxazole, amoxicillin, tetracycline, erythromycin, or rovamycin during the 4 weeks before the visits were excluded. For analyses of seroprevalence and changes in immune status, we excluded all participants who reported the receipt of any meningococcal vaccine during 2003 or any vaccine containing W-135 antigen at any time. IgG antibody geometric mean concentrations (GMCs) and SBA geometric mean reciprocal titers (GMTs) are reported. For all serogroups, IgG concentrations у2 mg/mL and SBA titers у8 were considered to be putatively protective [20, 21] . For serogroup W-135, alternative analyses were performed with an IgG cutoff of 1 mg/mL. Changes in carriage prevalence between visits 1 and 5 were tested by McNemar's exact test. Trends in the seroprevalence by age were tested using logistic regression with the following age categories: 4-8 years, 9-13 years, 14-18 years, 19-23 years, and 24-29 years. Differences in seroprevalence between visits 1 and 5 were considered to be significant when the 95% confidence interval (CI) for the mean reciprocal difference did not include 0. The correlation between log-transformed IgG concentrations and SBA titers was calculated as the Pearson's correlation coefficient and tested by univariate linear regression. All analyses took into account design effect (except for McNemar's test) and were performed using STATA Intercooled (version 9.0; StataCorp).
RESULTS

Inclusion, follow-up, and population characteristics.
A total of 512 individuals were recruited, of whom 3 did not meet the age criteria and 21 did not attend visit 1. Of the 488 remaining individuals, 451 (92%) had oropharyngeal swab samples collected at all 5 visits. At visits 1 and 5, 488 and 474 serum samples were obtained, respectively. The age of mean ‫ע‬ SD participants was years, and 43% of participants were 14.9 ‫ע‬ 6.7 female. Five participants reported a history of meningitis, and 5 participants !8 years old (4%) had malnutrition. Five participants reported prior vaccination with quadrivalent meningococcal vaccine (which included W-135 antigen), 2 reported vaccination with quadrivalent meningococcal vaccine during the study, 1 reported vaccination with bivalent A/C meningococcal vaccine during the study, 1 reported vaccination with meningococcal vaccine of unknown valence during the study, and 92% of participants reported having received A/C meningococcal vaccine during a mass vaccination campaign during 2001 putatively protective SBA titers against serogroup A was higher than that with putatively protective SBA titers against serogroup W-135 (76% vs. 24%), but this difference was small in participants !15 years old (28% vs. 19%) (table 2). At visit 5 (figure 1), for which more serum samples underwent SBA testing, bactericidal titers against serogroup A were higher than those against serogroup W-135 in all age groups. SBA titers against serogroup A were age dependent (test for trend at visit 5, ) but those against serogroup W-135 were not (figures P p .06 1 and 2).
For all serum samples from the random subsample of participants tested at visits 1 and 5, the coefficients of correlation between SBA titers and specific IgG concentrations for serogroup A and serogroup W-135 ranged between 0.30 and 0.57 (for all, ). When serum samples were evaluated for the P ! .05 presence or absence of putatively protective levels, IgG and SBA results were congruent for 68% of 164 samples tested against serogroup A and 82% of 190 samples tested against serogroup W-135. In serum samples tested against serogroup A, the majority with discordant results had high IgG concentrations and low SBA titers (83% of 53 serum samples); in serum samples tested against serogroup W-135, the majority with discordant results had low IgG concentrations and high SBA titers (68% of 34 serum samples).
Loss and acquisition of specific IgG and SBA. Specific IgG and SBA levels for all serogroups were similar at visits 1 and 5, except for anti-A SBA, although the smaller number of serum samples tested at visit 1 may limit the comparison (figure 1). Loss of putatively protective IgG concentrations between visits 1 and 5 was common for serogroups W-135 and Y but rare for serogroups A and C (table 3) . This difference was less pronounced for SBA, but loss of putatively protective SBA titers was more common for serogroup W-135 than for serogroup A. Acquisition of putatively protective IgG concentrations was relatively common for serogroups A and C and rare for serogroups W-135 and Y; similarly, acquisition of putatively protective SBA titers was common for serogroup A and rare for serogroup W-135. For both serogroup A and serogroup W-135, acquisition of putatively protective specific IgG and SBA levels generally did not occur in the same participant.
Association between carriage and immune status. At visit 1, participants who carried a serogroup W-135 strain at least once during the study ( ) had an anti-W-135 IgG GMC n p 23 of 0.57 mg/mL (95% CI, 0.29-1.13 mg/mL), and in noncarriers of serogroup W-135 ( ) this value was 0.43 mg/mL (95% n p 441 CI, 0.39-0.48 mg/mL); the anti-W-135 SBA GMT was 27.52 (95% CI, 2.73-277.32) for carriers and 6.09 (95% CI, 3.85-9.64) for noncarriers. These data were almost identical at visit 5. In W-135 carriers and noncarriers, the mean changes in anti-W-135 IgG concentrations between visit 1 and visit 5 were 0.85 mg/mL (95% CI, 0.51-1.41 mg/mL) and 0.73 mg/mL (95% CI, 0.68-0.79 mg/mL), respectively; the mean changes in SBA titers were 1.52 (95% CI, 0.46-5.08) and 1.02 (95% CI, 0.83-1.26), respectively. At both visit 1 and visit 5, SBA titers 11000 were more frequent in W-135 carriers than in noncarriers (26% vs. 2%; , Fisher's exact test). Participants with such per-P ! .001 sistently high SBA titers did not differ from other participants by number or duration of carriage events, age, or vaccination status.
In the 23 participants who carried serogroup W-135 strains at least once during the study, at baseline, 20 had anti-W-135 IgG concentrations !2 mg/mL, of whom 2 subsequently had an increase by a factor of 2, to у2 mg/mL; 14 had anti-W-135 SBA titers !8, of whom 2 subsequently had an increase (table Figure 1 . Serogroup-specific IgG geometric mean concentrations (GMCs) and serum bactericidal antibody (SBA) geometric mean reciprocal titers (GMTs), by age group, in Bobo-Dioulasso, Burkina Faso. Serum samples that were obtained at visit 1 (V1), which occurred 3-15 February 2003, and at visit 5 (V5), which occurred 27 May-7 June 2003, were tested. At V1 and V5, a total of 115 and 114 samples from participants 4-8 years old, 92 and 90 samples from participants 9-13 years old, 126 and 121 samples from participants 14-18 years old, 96 and 93 samples from participants 19-23 years old, and 48 and 46 samples from participants 24-29 years old were tested for serogroup-specific IgG. A random subsample was chosen for SBA testing, and at V1 and V5, a total of 19 and 24 samples from participants 4-8 years old, 9 and 14 samples from participants 9-13 years old, 22 and 28 samples from participants 14-18 years old, 12 and 15 samples from participants 19-23 years old, and 6 and 11 samples from participants 24-29 years old were tested for anti-A antibody. In addition, a total of 24, 14, 28, 15, and 11 samples from the respective age groups were tested for anti-W-135 antibody at both visits. Dark gray bars denote anti-A levels at V1, light gray bars denote anti-A levels at V5, black bars denote anti-W-135 levels at V1, and hatched bars denote anti-W-135 levels at V5. Error bars denote SEs. Putatively protective levels were defined as у2 mg/mL, for IgG concentrations, and у8, for SBA titers. For serogroup-specific IgG testing, a total of 114 samples from participants 4-8 years old, 90 samples from participants 9-13 years old, 121 samples from participants 14-18 years old, 93 samples from participants 19-23 years old, and 46 samples from participants 24-29 years old were obtained at visit 5 (27 May-7 June 2003) . A random subsample was chosen for SBA testing, and a total of 19, 9, 22, 12, and 6 samples from the respective age groups were tested at visit 5. Gray bars denote anti-A levels, and black bars denote anti-W-135 levels. Error bars represent 95% confidence intervals. 4). There was no difference in these patterns by age or delay between carriage and follow-up serological assessment. There was no association between carriage of any N. meningitidis strain and acquisition of putatively protective anti-W-135 SBA titers (8% acquisition in carriers vs. 6% acquisition in noncarriers 
DISCUSSION
This prospective study was conducted in a cohort of young persons living in an urban area of Burkina Faso during 2003, which was 1 year after a campaign for mass vaccination with A/C meningococcal polysaccharide vaccine was undertaken and when there was high coverage in 2-29-year-olds. The peak weekly meningitis incidence in 2002 and 2003 was between 3 and 4 cases per 100,000 persons. Parallel active surveillance showed that there was a hyperendemic meningococcal meningitis incidence (annual rate in persons !1 year old, 77 cases/ 100,000 persons; annual rate in persons 114 years old, 5 cases/ 100,000 persons), which was, during 2002, primarily due to serogroup W-135 and, during the study period, due to both serogroup A and W-135 [11] .
Within this context, we found a low prevalence of putatively protective levels of IgG and SBA against serogroup W-135 in the presence of moderate serogroup W-135 carriage and high IgG concentrations and relatively high SBA titers against serogroup A, whereas no serogroup A carriage was detected. We found that serogroup W-135 carriage infrequently induced protective immunity, whereas natural immunity against serogroup W-135 was frequently lost and did not seem to prevent carriage. In contrast, serogroup A immunity was infrequently lost, frequently acquired, and may have prevented carriage of any N. meningitidis strain.
These findings have several implications for meningococcal vaccination in the African meningitis belt. First, it is surprising that, despite substantial serogroup W-135 carriage and disease incidence, the population has not acquired putative immune protection against this serogroup. An earlier study in an unvaccinated Nigerian population demonstrated high anti-A and anti-C antibody titers associated with a carriage point prevalence of !2% [22] , suggesting that the serogroup W-135 carriage level we documented could have induced population immunity. Also, unvaccinated African populations that have serogroup A epidemics usually have developed (bactericidal) antibody against serogroup A [22, 23] , which we could not confirm for serogroup W-135 in Bobo-Dioulasso.
Although most serogroup W-135 carriers did not develop an immune response to carriage, approximately a quarter of them already had very high SBA titers at baseline-a characteristic that was rare in those who did not carry serogroup W-135. Because of the high titers in this subset of serogroup W-135 carriers, we found a high SBA GMT when all serogroup W-135 carriers were analyzed; such a finding has led other study groups (e.g., those studying serogroup A) to hypothesize that carriage induces immunity [22] . Before the present study was undertaken, the 6 persons in this subset of carriers may have had an immune response to carriage under specific environmental or individual circumstances that merit further investigation.
To our knowledge, our study is the first to evaluate, on an individual level, the immune response to serogroup W-135 carriage. Our findings contrast with those of an earlier study of US military recruits, which showed that 87% of serogroup B or C carriers had an increase in SBA titers against A, B, or C heterologous strains, compared with no increase in noncarriers [6] . Another study showed that carriage of nonserogroupable N. meningitidis strains stimulated an increase in heterologous SBA titers against serogroup A, B, C, or Y [7] . A third study, however, reported the absence of an increase in SBA titers against serogroups A, B, C, or Y after serogroup A or B carriage [24] . Because we used reference strains for SBA analyses, we cannot exclude the possibility that there was some increase in SBA titers against the homologous (i.e., identical) strain after carriage, as was described in these studies, but we did not see the expected accompanying serogroup-specific IgG antibody increase. Taken together, these data suggest that poor immune induction by serogroup W-135 carriage, compared with that induced by carriage of other serogroups, may explain the low population immune level we found in our study. This poor immune response despite carriage of serogroup W-135 may be due to some feature of W-135 capsular regulation during carriage or to host characteristics unique to the study population. Putatively protective levels of anti-W-135 IgG and SBA were lost in 50% and 20% of participants, respectively, after 4 months. There are no directly comparable data in the literature on persistence of naturally acquired anti-W-135 antibody or SBA, but some polysaccharide vaccine trials in adults and children have reported a relatively rapid loss of specific IgG or SBA [25] [26] [27] . Because a substantial proportion of anti-A immunity in our study probably was vaccine induced, we cannot compare the durations of protective antibody titers against serogroups A and W-135. Nevertheless, our data are consistent with the hypothesis that there is a shorter duration of immunity against serogroup W-135, compared with that against serogroup A.
In conclusion, these data indicate that the natural immune response to serogroup W-135 antigen is poor and short lived, which is of concern for the use of W-135 polysaccharide vaccines in Africa outside of the context of epidemic control. Together with the data on low preexisting immunity, these findings emphasize the need for a conjugate vaccine that includes W-135 antigen; recently, immunogenicity induced by a conjugate vaccine in young children was shown to be greater and of longer duration than that induced by a polysaccharide vaccine [27] .
The second major finding of our study was the absence of serogroup A carriage throughout the study period. Because 11 serogroup A meningitis cases (9 in children !4 years old) were observed by parallel surveillance in Bobo-Dioulasso during this period [11] , we assume that serogroup A strains were circulating. The prevalence of serogroup A carriage could have been underestimated for several reasons: given the study sample size, the upper limit of the 95% CI for serogroup A carriage prevalence was 1% [28] , pharyngeal swabbing probably underestimates meningococcal carriage [29] , and the swabbing intervals may have been too long to detect short episodes of carriage. Such short episodes of carriage may explain the relatively common acquisition of putatively protective specific IgG or SBA levels against serogroup A in our study. This latter finding may also have resulted from natural exposure to cross-reacting antigens such as Bacillus pumilus or certain Escherichia coli types, whose capsular polysaccharides are known to be cross-reactive with N. meningitidis serogroup A capsular polysaccharides [30, 31] .
Other studies have described epidemic or hyperendemic disease incidence despite very low carriage prevalence [10, 32] . In combination with the higher serogroup W-135 carriage prevalence, this finding indicates that serogroup A strains are less frequently transmitted but are more virulent than are serogroup W-135 strains. Explanations for the lower transmissibility of serogroup A strains may include some unknown characteristics of the circulating serogroup A strains or competition with the circulating serogroup W-135 strains. High population seroprevalence after mass vaccination campaigns is an unlikely explanation, given that earlier studies have indicated that polysaccharide vaccines do not reduce carriage prevalence over the long term [33] [34] [35] .
The low ratio of serogroup A carriage to disease in our study underlines the possibility that, if the direct effect of a future serogroup A conjugate vaccine in Africa is limited by poor routine coverage, then the vaccine will have to be highly effective in reducing carriage and preventing transmission if all or the great majority of cases in situations of hyperendemicity are to be prevented. Consequently-and this is an even more important issue because serogroup A carriage prevalence is so low-the efficiency of an immunization program may depend on targeting population groups most susceptible for serogroup A carriage. Well-powered carriage studies are needed to define these susceptible groups.
The third major finding of our study concerns the immunological measurements. For serogroup A and serogroup W-135, we found only limited correlations between SBA titers and specific IgG concentrations, both in prevalence and in acquisition. This supports the concept that, for serogroup A, cross-reacting antigens induce low-avidity antibody; additionally, inhibiting factors such as IgA antibody may reduce bactericidal activity of IgG antibody in some individuals. This may be especially important in sub-Saharan Africa, as has been recently suggested by a study of natural immunity against serogroup A in Sudan [23] . For serogroup W-135, our data suggest that serum bactericidal activity may exist at IgG concentrations much lower than 2 mg/ mL; this hypothesis is supported by the results of a recent study in young children in the United States [27] .
Against serogroup C, SBA titers у8 (using baby rabbit complement) are established as the surrogate of protection after serogroup C conjugate vaccination, and against serogroup A, IgG concentrations 12 mg/mL are considered to be protective [20] . We found that serogroup W-135 induced only poor and short-lived immunity, as defined by these criteria of immunogenicity, but we cannot be sure whether this truly represents low population protection against serogroup W-135. Our data emphasize the need to confirm correlates of protection for serogroup W-135 and to show clinical vaccine efficacy against this serogroup.
Because of the study logistics, our sample did not include children !4 years old, and, thus, our conclusions may not apply to this age group. We cannot exclude the possibility that serogroup A strains are frequently carried by young children and that this carriage contributes to serogroup A meningococcal disease in older persons. Serogroup W-135 strains have caused large-scale epidemics in Burkina Faso and are still frequently carried, whereas natural immunity is rare and of short duration and does not appear to protect against carriage. Consequently, conjugate vaccines that include W-135 antigen will likely be of substantial benefit in the region. Very low serogroup A carriage in association with substantial disease incidence suggest that a serogroup A conjugate vaccine needs to be highly effective in carriage reduction and needs to be targeted to potential carriage risk groups, to prevent hyperendemic disease in sub-Saharan Africa.
